Christoph Koenen

Dr. Koenen is currently heading all cardiovascular development, as well as CV Medical within BMS. Dr. Koenen joined BMS in 2011, and has worked in different medical and development functions in Europe, as well as in the US. He joined BMS from Novo Nordisk, where his last position was Vice President and Head of Global Medical Affairs. During his 9 years with Novo Nordisk, Dr. Koenen had worked on the development of several compounds for Novo Nordisk, including three different insulin compounds, as well as launched several compounds successfully. Before joining Novo Nordisk in 2002, Dr. Koenen worked for GlaxoSmithKline in London, UK, as well as in Germany. While at GlaxoSmithKline, Dr. Koenen was responsible for the development of anti-diabetic compounds. Dr. Koenen received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany, in 1994. He also holds a Master of Business Administration from Schiller International University. In addition to attending Heidelberg Medical School, Dr. Koenen attended medical school in Johannesburg, South Africa; Basel, Switzerland; and Columbia, Missouri, USA. As a board-certified internist and diabetologist, Dr. Koenen has researched the influence of ACE-Inhibitors on diabetic nephropathy, as well as the effect of insulin treatment on weight gain in obese type 2 diabetes patients.



Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.